Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

DALLAS, TX / ACCESSWIRE / January 24, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH):

BPTH : 2.19 (-2.67%)
Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

Bio-Path Holdings, Inc. (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize(R) antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock

Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path: 3Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Thursday reported a loss of $3.1 million in its third quarter.

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Reports Third Quarter 2018 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET

BPTH : 2.19 (-2.67%)
Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path: 1Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Wednesday reported a loss of $1.9 million in its first quarter.

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Reports First Quarter 2018 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Stock Monitor: Bio-Path Holdings Post Earnings Reporting

ARDM : 0.1200 (-73.91%)
BPTH : 2.19 (-2.67%)
Bio-Path Leukemia Combo Study Shows Positive Early Data

Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

LGND : 117.18 (-1.45%)
ENTA : 98.02 (-2.42%)
REGN : 418.62 (-0.92%)
BPTH : 2.19 (-2.67%)
Bio-Path Holdings Reports Full Year 2017 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time.

BPTH : 2.19 (-2.67%)
Bio-Path Holdings Announces Publication in The Lancet Haematology

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 2.19 (-2.67%)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX +0.04
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar